BC
AXDX

Bartlett & Co’s Accelerate Diagnostics AXDX Stock Holding History

Bartlett & Co’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$0 Sell
100
-100
-50% -$529 ﹤0.01% 1199
2023
Q3 		$1K Hold
200
– – ﹤0.01% 1094
2023
Q2 		$2K Hold
200
– – ﹤0.01% 1050
2023
Q1 		$1K Hold
200
– – ﹤0.01% 1003
2022
Q4 		$1K Hold
200
– – ﹤0.01% 1036
2022
Q3 		$3K Hold
200
– – ﹤0.01% 978
2022
Q2 		$2K Hold
200
– – ﹤0.01% 1152
2022
Q1 		$3K Buy
+200
New +$5.7K ﹤0.01% 953

Other funds holding AXDX

GAM
Griffin Asset Management New York $887M AUM 21.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CI
Chartist Inc Seal Beach, California $139M AUM
TWA
TCI Wealth Advisors Tucson, Arizona $1.88B AUM 21.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bartlett & Co's AXDX Position: Q4 2023 in Review

Bartlett & Co reduced its Accelerate Diagnostics (AXDX) stake by 50% in Q4 2023, selling an estimated $529 and leaving 100 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1199.

Bartlett & Co first reported a position in AXDX in Q1 2022 and has held it in 8 quarters since. The position peaked at $3K in Q3 2022. 43 funds tracked by Wall St. Rank hold AXDX as of Q4 2023.

  • Bartlett & Co held 100 shares of Accelerate Diagnostics worth $0 as of Q4 2023.
  • Bartlett & Co sold 100 Accelerate Diagnostics shares in Q4 2023, an estimated $529.
  • Accelerate Diagnostics made up ﹤0.01% of Bartlett & Co's portfolio in Q4 2023, its #1199 holding.
  • Bartlett & Co first reported a position in Accelerate Diagnostics in Q1 2022 and has held it in 8 quarters since.
  • Bartlett & Co's Accelerate Diagnostics position peaked at $3K in Q3 2022.
  • 43 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2023.

Based on Bartlett & Co's 13F filing for Q4 2023, filed 8 Jan 2024.